DOCSLIB.ORG

Adult Irritable Bowel Syndrome (IBS) IBS Prevalence – 10-20%.Symptoms Often Noticeable 20-30Yrs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adult Irritable Bowel Syndrome (IBS) IBS Prevalence – 10-20%.Symptoms Often Noticeable 20-30Yrs Adult Irritable Bowel Syndrome (IBS) IBS Prevalence – 10-20%.Symptoms often noticeable 20-30yrs. Make a positiv e diagnosis based on symptoms rather than exhaustive investigations History Absolute Red Flags - Refer Urgently: Consider in anyone with a history of: Abdominal, pelvic or rectal masses Abdominal pain/discomfort eased by defecation or associated with altered stool form or frequency and at least 2 of:- Ascites Unexplained increased urinary urgency Bloating, distension, tension or hardness >40 years jaundice or unexplained weight loss Change in stool passage – straining, urgency, incomplete evacuation Bristol Sto ol Ch art (can be useful) and abdominal pain >50 years with unexplained rectal bleeding Symptoms worse with eating >60 years with iron deficiency anaemia or Passage of mucus change in bowel habit or weight loss and one Other features such as lethargy, nausea, backache and bladder symptoms are of: change in bowel habit/back pain/ abdominal pain/nausea/vomiting/new- onset common in people with IBS and may be used to support the diagnosis. Use Rom e Self-fill Q uestion naire diabetes Consider Urgent Referral Inv estigations Examination – Abdominal + rectal +/- pelvic examination Sy stemically unwell Consider arranging the following inv estigations to exclude an alternative diagnosis - Nocturnal symptoms Strong f amily history of bowel or ovarian or breast or Full blood count (FBC), Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), stool Microscopy, culture and sensitivity (MC&S), thyroid function (TFT) prostate cancer Coeliac screen – Tissue Transglutaminase (TTG) and Immunoglobulins Persistent abdominal distension (NB Consider IgA deficiency with negative TTG) Pelv ic or abdominal pain Consider Cancer antigen 125 (Ca125) in female patients Early satiety/loss of appetite Raised platelet count Faecal Calprotectin (FC): see FC pathway for full details Hav e a low threshold for thinking about rarer Consider faecal calprotectin in patients in whom there is diagnostic uncertainty but no cancers: pancreatic (multidisciplinary diagnostic red flags and in whom specialist assessment or input is being considered. centre) and ov arian (simultaneous CA125 and urgent pelvic ultrasound scan) < 50 50-200* >200* Refer to Gastroenterology Urgent referral *See overleaf re Repeat in 2 to 4 weeks and consider IBS Result remains indeterminate Whittington advice. If negative manage as above for or >200 If faecal calprotectin >200* as Reference Ranges IBS. If still indeterminate or positive and suggests active bowel inflammation. symptoms persist then refer to consultant Routine referral <5 0 If indeterminate level and: Diagnosis and management of IBS If persistent diarrhoea or clinical If meet IBS diagnosis criteria no need for scoping, imaging, faecal occult blood etc Identify subtype: Constipation predominant = IBS-C concern or Diarrhoea predominant = IBS-D If resistant to treatment Or mixed = IBS-M Dietary adv ice – give BDA Patient Leaflet Psychological therapies – not Pharmacological treatments Yoghurt – consider 4 week trial probiotic ( consider if relevant to the prescribable) yoghurt twice a day. Pain relief individual or if symptoms st refractory to treatment Trial of a low FODMAP diet (fermentable 1 line antispasmodics oligosaccharides, disaccharides, Hyoscine butylbromide - 20mg four times a monosaccharides and polyols) diet has been Refer to iCOPE for Cognitive Behavioral shown to achieve relief of overall gastro intestinal day or Therapy (CBT) (GI) symptoms in 86% of patients particularly Mebeverine hydrochloride - 135mg or where there are symptoms of bloating, flatus and Hypnotherapy endorsed by NICE, abdominal pain three times a day 20min before meals however needs PoLCE approval Peppermint oil (if hyoscine butylbromide or IBS- Constipation: add up to a maximum of 1 mebeverine not suitable or ineffective) - There is currently limited evidence for tablespoon/day of linseeds whole or ground to food Biofeedback/relaxation therapies and 1-2 capsules herbal medicines. These are therefore and take with small glass water Three times a day 20 min before meals not recommended locally. Fibre – discourage eating insoluble fibre e.g. bran. If nd need fibre eat soluble fibre e.g. ispaghula/oats 2 line – Tricyclics (unlicensed) amitriptyline See fibre sheet – 5-10mg at night, max 30mg Please refer to the Summary of Fluids >8 cups (2 litres) a day water and non- rd carbonated non-caffeinated drinks 3 line SSRI (unlicensed) if above Product Characteristics (SPC) of any ineffective/not tolerated – citalopram 20mg drug considered. This pathway has Lactose intolerance – can cause similar symptoms daily, sertraline 50mg daily, fluoxetine 20mg been developed from published to IBS- D. Consider trial of lactose free diet 2-4 daily guidance in collaboration with local weeks to see if symptoms improve. gastroenterologists. This guidance is Constipation – Ispaghula husk (see BNF for to assist GPs in decision making and is dose)+/-macrogol oral powder 1-2 NICE DG11 Oct 13, NICE 2008 CG61, http://www.bda.uk.com/foodfacts/IBSfoodfacts.pdf, BMJ 2012;345:e5836 sachets/daily . Drink with pleanty of fluid not intended to replace clinical Refer to current BNF or SPC for full medicines information Clinical Contact for this pathway for queries: camden.pathways@nhs. net judgement Pathway Created 2014. Updated May 2018 Diarrhoea - loperamide (see BNF for dose). Approved by: Clinical Cabinet 07/2018, Medicines Management and Commissioning committees - 08/18 Review due 08/2021 Faecal calprotectin (FC) Pathway Please refer to the Summary of Product Characteristics (SPC) of any drug considered. This pathway has been developed from published Consider faecal calprotectin in patients in whom there is diagnostic uncertainty but no red guidance in collaboration with local flags and in whom specialist assessment/input is being considered. gastroenterologists. This guidance is to assist GPs in decision making and is not intended to replace clinical judgement Investigations: Faecal Calprotectin (FC) - request and send stool sample to lab Probable IBS. Low probability of organic pathology. Lifestyle advice and dietary advice sheet. Increase Note: Stop NSAIDs 4 weeks prior to FC testing and physical activity. exclude conditions as with other causes FC Consider: Dietetic referral Antispasmotic medication (Hyoscine butylbromide mebeverine, peppermint oil) Age 16-40 years Treat as IBS. Refer to secondary care FC negative - <50μg/g if suspicious symptoms even if FC negative Whittington Hospital ranges Age >40 years Treat as IBS. Consider investigating only- >50mg /kg* change in bow el habits. Be alert for ovarian cancer in females >50years FC indeterminate 50-200μg /g* Whittington Hospital ranges only 50-150mg /kg* Consider other causes of inflammation .Repeat test after 4 weeks. If negative manage as above FC positive - >200μg /g* Routine general GI for IBS. If still indeterminate or clinic referral Whittington Hospital ranges positive and symptoms persist then only- >150mg /kg* refer to consultant Other causes of a positive FC – Moderate probability of organic Gastro Intestinal Infections- Giardia, bacillary dysentery, viral pathology. gastroenteritis, helicobacter gastritis Malignancy, - colorectal cancer, gastric carcinoma, intestinal Urgent IBD clinic referral lymphoma Drugs Miscellaneous- NSAID, proton pump inhibitor, gastro- oesophageal reflux disease (GORD), coeliac disease, diverticular disease, protein losing/autoimmune enteropathy, microscopic colitis, liver cirrhoisis Faecal Calprotectin (FC) Calprotectin is a stable protein that is released into faeces when neutrophils gather at the site of any G.I tract inflammation. Calprotectin can provide a non -invasive, inexpensive and objective method for assessing patients who may require referral for additional procedures e.g. Colonoscopy or imaging studies. The faecal calprotectin test has a relatively high specificity and sensitivity (approximately 90%) for distinguishing between non-inflammatory bowel disorders (e.g. irritable bowel syndrome) and inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease). Calprotectin will also be elevated in some cases of GI tract malignancy (e.g. colorectal cancer). Calprotectin concentrations relate well to disease activity in the inflammatory bowel diseases and can therefore be used to monitor therapy. The test is non-invasive and can be used on adults and children (not neonates); the same reference range appears to apply to both. Sample Requirements. Random faecal sample (any time of day, no dietary restrictions required) in a plain universal container and approximately 1 gram in weight. Should not be exposed to temperatures >30°C NOTE: Samples grossly contaminated with blood are unsuitable for FCALP analysis. *Whittington Hospital (WH) sends all FC samples to Rotherham Hospital who use the Immundiagnostik IDK Calprotectin ELISA kit and the interpretative thresholds for adults are as follows: >50mg/kg regarded as positive 100 to 150 mg/kg indicative of bowel inflammation >150 mg/kg consistent with active IBD .
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Norfolk & Waveney Prescriber
    The Norfolk & Waveney Prescriber Issue 119 April 2017 For Primary and Secondary Care Health Professionals in Norfolk & Waveney In this issue: Prescribing Safety News: MHRA Drug Safety Updates 2 TAG and Commissioning News 3-4 Drugs – discontinued, shortages and prices 5-6 Drugs – supply issues 7-8 Guidance and Policy News: - National: “NICE Bites” & NICE guidance 9-10 Guidance and Policy News: - Local: Key Message Bulletins 11-12 Cost-effective Prescribing Tips: 13 Ophthalmic Special Order products Atorvastatin Hot Topic: Multimorbidity and Polypharmacy 14 Prescribing Safety: Medicines and Serotonin Syndrome 15-16 Prescribing Advice: Metformin, Finasteride, and Inhalers 17-18 New Medicines & Indications News 19 Feedback and comments on this edition to [email protected] / 01603 257035 Prescribing & Medicines Management Team – 1 NEL CSU Anglia Prescribing Safety News Main points from MHRA Drug Safety Updates February - March 2017 Articles relevant to Primary Care and Secondary Care: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes. Advice for healthcare professionals: o carefully monitor patients receiving canagliflozin who have risk factors for amputation, such as poor control of diabetes and problems with
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Effect of Diazepam and Hyoscine Butylbromide on Response to Secretin and Cholecystokinin-Pancreozymin in Man
    Gut: first published as 10.1136/gut.17.5.351 on 1 May 1976. Downloaded from Gut, 1976, 17, 351-353 Effect of diazepam and hyoscine butylbromide on response to secretin and cholecystokinin-pancreozymin in man J. H. B. SAUNDERS, GUYA MASOERO, AND K. G. WORMSLEY' From the Department of Therapeutics, University of Dundee, Dundee SUMMARY Ten subjects received secretin and cholecystokinin or, in duplicate tests, the two hor- mones together with either diazepam or diazepam plus hyoscine butylbromide in order to determine whether these drugs, which are often used during retrograde endoscopic cannulation ofthe pancreatic duct, affect pancreatic and biliary secretion in response to the hormones. Diazepam with hyoscine butylbromide reduced the secretion of trypsin into the duodenum and delayed the appearance of both trypsin and bilirubin in duodenal aspirate. These effects must be taken into account when interpreting pancreatic and biliary responses measured during direct cannulation of the pancreatic duct. Endoscopic retrograde cannulation of the pancreatic vents in the antrum. Secretin (1 clinical unit/kg-h) duct has recently been used to measure pancreatic and cholecystokinin-pancreozymin (1 Ivy unit/ function by collecting the pancreatic juice directly kg-h) were administered for 45 minutes by continuous from the pancreatic duct during stimulation with intravenous infusion in 0 15 mol/1 sodium chloride. hormones et The exogenous (Cotton al., 1974; Gregg hormones had been purchased from the GIH http://gut.bmj.com/ et al., 1975; Robberecht et
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Symptom Control Medication & the Dying Person
    SYMPTOM CONTROL MEDICATION & THE DYING PERSON LITERATURE REVIEW, AUDIT RESULTS & NEW STANDARDS & GUIDELINES 27TH NOVEMBER 2014 SYMPTOM CONTROL MEDICATION & THE DYING PERSON GUIDELINE DEVELOPMENT GROUP RUTH CLARK MOIRA WATSON DR AVERIL FOUNTAIN DR AMARA NWOSU PHILIP GREEN CHRISTINE RILEY DEBORAH JONES DR CLAIRE ROBINSON DR ANDREW KHODABUKUS SESSION OUTLINE • Patient, Carer and Public Involvement • Literature Review • Existing Standards & Audit Results POWERPOINT • Updated StandardsPRESENTATION & Guidelines JULY 2012 V1.0 PROVENANCE • 2006 – initial guidelines produced • 6th March 2014 – Review meeting of CMPCNAG, majority quorate vote to review guidelines by e-Vote • Meetings of membership of Symptom Control Medication & the Dying Person Guideline Development Group POWERPOINT – 29th April 2014 – 27th May 2014 PRESENTATION th – 24 July 2014 JULY 2012 – 2nd September 2014 – 3rd October 2014 V1.0 – 7th November 2014 POWERPOINT PATIENT, CARERPRESENTATION AND PUBLIC INVOLVEMENTJULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT • PCPI representative Christine Riley – Experience of family members dying including her sister – Involved in review of our proposal and perspectives of issues pertinent to PCPI POWERPOINT PRESENTATION JULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT THE ROLE OF MEDICATION • Medications use is ‘part and parcel’ of management dying. • What the types of medications used are less important to PCPI • What is more important is that there is a plan in place that these would addressPOWERPOINT symptoms to make the patient comfortable and that what the medications were forPRESENTATION – which symptom groupsJULY 2012 were being addressed. is communicated well with V1.0 the family. PATIENT, CARER & PUBLIC INVOLVEMENT EXPERIENCE • Some families are distressed by the dying phase – they have no experience of it – no accurate POWERPOINT representation on the media of whatPRESENTATION it is actually like.
    [Show full text]